SU1398869A1 - Method of treatment of gastric and duodenal peptic ulcers - Google Patents
Method of treatment of gastric and duodenal peptic ulcers Download PDFInfo
- Publication number
- SU1398869A1 SU1398869A1 SU853970758A SU3970758A SU1398869A1 SU 1398869 A1 SU1398869 A1 SU 1398869A1 SU 853970758 A SU853970758 A SU 853970758A SU 3970758 A SU3970758 A SU 3970758A SU 1398869 A1 SU1398869 A1 SU 1398869A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- ulcers
- gastric
- treatment
- methyluracil
- peptic ulcers
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 230000002496 gastric effect Effects 0.000 title claims 2
- 208000008469 Peptic Ulcer Diseases 0.000 title 1
- 230000002183 duodenal effect Effects 0.000 title 1
- 208000025865 Ulcer Diseases 0.000 claims abstract description 12
- 231100000397 ulcer Toxicity 0.000 claims abstract description 12
- 102000008186 Collagen Human genes 0.000 claims abstract description 6
- 108010035532 Collagen Proteins 0.000 claims abstract description 6
- 229920001436 collagen Polymers 0.000 claims abstract description 6
- 230000035876 healing Effects 0.000 claims abstract description 6
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 claims abstract description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 4
- 239000008055 phosphate buffer solution Substances 0.000 abstract description 3
- 230000029087 digestion Effects 0.000 abstract 1
- 229940048832 ranitidine 150 mg Drugs 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000007547 defect Effects 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000015877 Duodenal disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018595 duodenum disease Diseases 0.000 description 1
- 238000002181 esophagogastroduodenoscopy Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000010644 positive regulation of cell differentiation Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к гастроэнтерологии . Цель изобретени -уменьшение деформации слизистой при заживлении зв. Производ т обкапывание звы раствором, содержащим 0,5% коллаген , 0,4% метилурацил и фосфатный бу- ферньй раствор. Больному назначают ранитидин по 150 мг 2 раза в сутки.This invention relates to gastroenterology. The purpose of the invention is to reduce the deformation of the mucous during healing of ul. The digestion of the ulcers is carried out with a solution containing 0.5% collagen, 0.4% methyluracil and phosphate buffer solution. The patient is prescribed ranitidine 150 mg 2 times a day.
Description
(Л(L
сwith
Изобретение относитс к медицине, в частности к гастроэнтерологии.This invention relates to medicine, in particular to gastroenterology.
Цель.изобретени - уменьшение деформации слизистой при заживлении г зв за счет преобладани процессов регенерации над процессами ее склерозировани .The purpose of the invention is to reduce the deformation of the mucous during the healing of r s due to the predominance of regeneration processes over the processes of its sclerosis.
Пример 1. Вольной А,, 23 лет, поступил в клинику с диагнозом: з- Ю венна болезнь две.надцатиперстной кишки. Исследование желудочного сока вы вило повышенную кислотность. При эзофагогастродуоденоскопии обнарухш- на зва до 0,8 см в диаметре, произ- 15 ведено обкалывание ЯЗвы раствором, содержащим 0,5% коллагена, 0,4% ме- тилурацила и фосфатный буферный раствор рН 7,0 до 100, в количестве 5 мл. Больному также был назначен ранити- 20 ин по 150 мг два раза в сутки. При контрольном эндоскопическом исследовании через 10 дн вы влено заживление звы, запохшекие дефекта гранул ционной тканью и эпнтелизаци 25 звы без развити рубца и сопутству- юпц-ей ему деформации.Example 1. Free A, 23 years old, was admitted to the hospital with a diagnosis of: Juvenile duodenal disease. The study of gastric juice revealed an increased acidity. With esophagogastroduodenoscopy of the nasal name up to 0.8 cm in diameter, the ulcers were punctured with a solution containing 0.5% collagen, 0.4% methyluracil and phosphate buffer solution pH 7.0 to 100, in an amount of 5 ml. The patient was also given ranit-20 in, 150 mg twice a day. A 10-day control endoscopic examination revealed healing of ulcers, breathless defects by granulation tissue, and epithelization of 25 ulcers without scar development and the deformation accompanying it.
Пример 2. Больна Ш„, 66 лет, находилась в клинике с диагнозом: звенна болезнь желудка, 30 От оперативного лечени больна отказалась . При рентгенологическом и эндоскопическом исследовани х обнаружена зва угла желудка до 1 см в диаметре. Больной назначено комплексное лечение. Кроме того, произедено однократное обкалывание з- ы раствором, содержащим 0,5% колагена , 0,6% метилурацила на фосфатом буферном растворе с рН 7„4, в 40 оличестве 6 мл. Через 12 дн при контрольном эндоскопическом исследовании звы и грубого рубца не обнаружено, отмечалс нежный рубец с эпителиза- ией дефекта слизистой.45Example 2. Patient Mr, 66 years old, was in the clinic with a diagnosis of gastric ulcer, 30 She refused surgical treatment. At radiological and endoscopic examinations, the stomach point was found up to 1 cm in diameter. The patient was prescribed a comprehensive treatment. In addition, a single injection was made of a solution containing 0.5% collagen, 0.6% methyluracil in phosphate buffer solution with a pH of 7–4, in 40% of 6 ml. After 12 days, a control endoscopic examination of the ulcers and a rough scar were not detected, a tender scar with epithelial mucous membrane was observed. 45
Как показали исследовани , регенераци слизистой желудка и 12-перстной кишки при обкальгоании звы коллагеко35Studies have shown that the regeneration of the mucous membrane of the stomach and duodenum during calcification of collaghex ulcer35
5 0 5 5 0 5
0 0 50 0 5
5five
вым материалом существенно отличалась от заживлени звы при обкальшании метилурацилом. Продуктивна фаза преобладала уже на 3-й сутки, следствием чего вилось ускоренное заполнение дефекта гранул ционной тканью и эпителизацией звы. Препарат, помимо стимулирующего действи на развитие соединительной ткани, оказывает вли ние не регенерацию слизистой оболочки желудка и 12-перстной кишки, чего нет у других препаратов. Эпите- лизаци дефекта наступает на 5-7 суток быстрее, чем в контроле, восстановление цитоархитектоники и секреторной де тельности фундальных желез наблюдаетс на 15-20-е сутки. Длительное сохранение препарата в стенке желудка нормализует процессы регенерации: на фоне выраженной стимул ции дифференцировки клеток происходит торможение фазы пролиферации, что вл етс новой качественной характеристикой коллагенового материала.Vym material was significantly different from the healing of ulcers when it was calcined with methyluracil. The productive phase prevailed already on the 3rd day, as a result of which an accelerated filling of the defect with granulation tissue and epithelization of ulcers occurred. The drug, in addition to its stimulating effect on the development of connective tissue, does not affect the regeneration of the mucous membrane of the stomach and duodenum, which other drugs lack. Epithelization of the defect occurs 5–7 days faster than in control, recovery of cytoarchitecture and secretory activity of the fundal glands is observed for 15–20 days. Prolonged preservation of the drug in the stomach wall normalizes regeneration processes: against the background of pronounced stimulation of cell differentiation, the phase of proliferation is inhibited, which is a new qualitative characteristic of the collagen material.
Клиническое использование раствора , содержащего коллаген, позвол ет добитьс заживлени звы через эпи- телизацию кратера звы в виде практически невидимого углублени в отличие от образовани грубого рубца при обкалывании звы другими препаратами , в частности метилурацилом.The clinical use of a solution containing collagen allows healing of the ulcers through epithelization of the ulcer crater in the form of a virtually invisible depression, in contrast to the formation of a rough scar when piercing the ulcer with other drugs, such as methyluracil.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU853970758A SU1398869A1 (en) | 1985-10-31 | 1985-10-31 | Method of treatment of gastric and duodenal peptic ulcers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU853970758A SU1398869A1 (en) | 1985-10-31 | 1985-10-31 | Method of treatment of gastric and duodenal peptic ulcers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1398869A1 true SU1398869A1 (en) | 1988-05-30 |
Family
ID=21203133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU853970758A SU1398869A1 (en) | 1985-10-31 | 1985-10-31 | Method of treatment of gastric and duodenal peptic ulcers |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1398869A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2241489C2 (en) * | 1998-02-27 | 2004-12-10 | Биора Биоэкс Аб | Matrix protein compositions for healing wound |
-
1985
- 1985-10-31 SU SU853970758A patent/SU1398869A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Толмач В.Д., Левин В.Ф. - Материалы III Всесоюзного съезда гастро- эйтерологов. М.-Л«, 1984, т.2, с. 269-270. ,(54) СПОСОБ ЛЕЧЕНИЯ ЯЗВ ЖЕЛУДКА И ДВЕНАДЦАТИПЕРСТНОЙ КИШКИ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2241489C2 (en) * | 1998-02-27 | 2004-12-10 | Биора Биоэкс Аб | Matrix protein compositions for healing wound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5591445A (en) | Smooth muscle chemical pacemaker | |
| US4565805A (en) | Pharmaceutical preparation for the treatment of peptic ulcer | |
| SU1398869A1 (en) | Method of treatment of gastric and duodenal peptic ulcers | |
| RU2159631C1 (en) | Method for stopping hemorrhages from gastroduodenal peptic ulcers | |
| RU2189822C2 (en) | Method for treating gastroduodenal ulcers complicated with scar-ulcerous stenosis of the upper departments of gastrointestinal tract | |
| Wirts et al. | A study of the effect of an anion exchange resin on gastric and duodenal secretions and gastric emptying | |
| RU2006225C1 (en) | Method of hemostasis in hemorrhagic gastritis | |
| RU2106149C1 (en) | Method to treat chronic ischemic disease | |
| SU921540A1 (en) | Sternotomy method | |
| SU1706624A1 (en) | Method for curing opiumism and morphinism | |
| RU2013092C1 (en) | Method of treatment of brain edema at tuberculosis meningoencephalitics | |
| Christensen et al. | Plasma growth hormone in acromegalic patients | |
| SU1061818A1 (en) | Method of treatment of pustular psoriasis | |
| RU2831547C1 (en) | Agent for treating trophic ulcers accompanying diabetic foot syndrome | |
| RU2819638C1 (en) | Method of treating chronic kidney disease with dalargin | |
| SU1147361A1 (en) | Method of treatment of duodenal peptic ulser | |
| RU2152214C1 (en) | Method for treating the cases of acute osteomyelitis | |
| RU2146884C1 (en) | Method for treating the cases of diffuse toxic goiter | |
| SU1748833A1 (en) | Method for treatment of stomach and duodenum ulcers | |
| SU1076124A1 (en) | Method of treatment of acute pancreatitis | |
| SU1725902A1 (en) | Method of children treatment with chronic tonsillitis | |
| RU2347573C1 (en) | Method for correction of endogenuous intoxication and prevention of undesirable side reactions of antituberculous medications in tuberculosis patients | |
| SU1050669A1 (en) | Method of determining vagotomy efficiency at peptic ulcer of stomach and duodenum | |
| RU2053788C1 (en) | Method of ulcer disease treatment | |
| SU1194418A1 (en) | Method of treatment of children having purulent destructive pneumonia |